- Current report filing (8-K)
07 Janeiro 2013 - 8:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported):
January 7, 2013
TARGETED MEDICAL PHARMA, INC.
(Exact name
of registrant as specified in its charter)
DELAWARE
|
000-53071
|
20-5863618
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
2980 BEVERLY GLEN CIRCLE, SUITE 301
LOS ANGELES, CA 90077
(Address
of principal executive offices)
(310) 474-9808
(Registrant’s
telephone number, including area code)
(Former name
or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
¨
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
TARGETED MEDICAL PHARMA, INC. (“THE
COMPANY”) CLAIMS THE PROTECTION OF THE SAFE HARBOR FOR “FORWARD-LOOKING STATEMENTS” WITHIN THE MEANING OF THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ARE NOT HISTORICAL FACTS. SUCH
FORWARD-LOOKING STATEMENTS, BASED UPON THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT OF THE COMPANY REGARDING, AMONG OTHER
THINGS, THE BUSINESS OF THE COMPANY, ARE SUBJECT TO RISKS AND UNCERTAINTIES, WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER FROM THE
FORWARD-LOOKING STATEMENTS. THE FOLLOWING FACTORS AND RISKS, AMONG OTHERS, COULD CAUSE ACTUAL RESULTS TO DIFFER FROM THOSE SET
FORTH IN THE FORWARD-LOOKING STATEMENTS: BUSINESS CONDITIONS IN THE U.S. AND ABROAD; CHANGING INTERPRETATIONS OF GENERALLY ACCEPTED
ACCOUNTING PRINCIPLES; REQUIREMENTS OR CHANGES ADVERSELY AFFECTING THE BUSINESS IN WHICH THE COMPANY IS ENGAGED; MANAGEMENT OF
RAPID GROWTH; INTENSITY OF COMPETITION; GENERAL ECONOMIC CONDITIONS; THE COMPANY’S ABILITY TO RAISE NECESSARY FUNDS; AS WELL
AS OTHER RELEVANT RISKS DETAILED IN THE COMPANY’S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. THE INFORMATION SET
FORTH HEREIN SHOULD BE READ IN LIGHT OF SUCH RISKS. THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE INFORMATION CONTAINED IN THIS
REPORT.
Item 7.01. Regulation FD Disclosure
Attached as Exhibit 99.1 to this Current
Report is the form of presentation that Targeted Medical Pharma, Inc. (the “Company”) expects to use in connection
with presentations to certain potential investors in the Company on January 8, 2013.
Item 8.01 Other Events
Attached as Exhibit 99.2 to this Current
Report is a press release that was distributed by the Company on January 7, 2013.
Item 9.01 Exhibits
(d) Exhibits
|
Exhibit
|
|
|
No.
|
Description
|
|
99.1
|
Presentation
|
|
99.2
|
Press Release dated January 7, 2013
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 7, 2013
|
TARGETED MEDICAL PHARMA, INC.
|
|
|
|
|
By:
|
/s/ William E. Shell
|
|
|
Name: William E. Shell, MD
|
|
|
Title: Chief Executive Officer
|
Targeted Medical Pharma (CE) (USOTC:TRGM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Targeted Medical Pharma (CE) (USOTC:TRGM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024